Search results for "TRANSITION"

showing 10 items of 3988 documents

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

2008

OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test…

AdultMalemedicine.medical_specialtyAdolescentUrologyUrinary systemUrologyContext (language use)urologic and male genital diseasesSensitivity and SpecificityCohort StudiesPredictive Value of TestsRisk FactorsCytologyBiomarkers TumormedicineCarcinomaHumansChildAgedRetrospective StudiesAged 80 and overGynecologyBladder cancerbusiness.industryNuclear ProteinsMiddle AgedPrognosismedicine.diseaseTransitional cell carcinomaUrinary Bladder NeoplasmsEpidermoid carcinomaPredictive value of testsCarcinoma Squamous CellFemaleNeoplasm Recurrence LocalbusinessBJU International
researchProduct

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell c…

2005

ABSTRACT Purpose: We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort. Methods: Univariate and multivariate logistic regression models targeted histologically confirmed disease recurrence, and focused on 2,542 patients with bladder TCC from 10 participating centers. Variables consisted of pre-cystoscopy voided urine Nuclear Matrix Protein 22 (NMP22) assay, urine cytology, age and gender. Resulting nomograms were internally validated with bootstrapping. Nomogram performance was explored graphically with Loess smoothing plots. Results:…

AdultMalemedicine.medical_specialtyAdolescentUrologyUrinary systemUrologyurologic and male genital diseasesLogistic regressionBladder neoplasmsnuclear matrix protein 22neoplasm stagingnomogramsBladder NeoplasmCytologyBiomarkers TumormedicineHumansStage (cooking)AgedNeoplasm StagingUrine cytologyAged 80 and overCarcinoma Transitional Cellmedicine.diagnostic_testbusiness.industryNuclear ProteinsMiddle AgedNomogramPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryNomogramsTransitional cell carcinomaUrinary Bladder NeoplasmsMultivariate AnalysisDisease ProgressionFemalebusiness
researchProduct

Neuromuscular and physiological variables evolve independently when running immediately after cycling

2015

International audience; During the early period of running after cycling, EMG patterns of the leg are modified in only some highly trained triathletes. The majority of studies have analysed muscle EMG patterns at arbitrary, predetermined time points. The purpose of this study was to examine changes to EMG patterns of the lower limb at physiologically determined times during the cycle-run transition period to better investigate neuromuscular adaptations. Six highly trained triathletes completed a 10 min isolated run (IR), 30 min of rest, then a 20 min cycling procedure, before a 10 min transition run (C-R). Surface EMG activity of eight lower limb muscles was recorded, normalised and quantif…

AdultMalemedicine.medical_specialtyAdolescentenergy-costperformance-levelBiophysicsNeuroscience (miscellaneous)submaximal exerciseBiologyTriathlonLower limbRunningPhysical medicine and rehabilitationEMGmuscle-fiber typeHeart ratemedicine[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Humansolympic-triathlonMuscle SkeletalCycle-runReproducibility[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Cyclingslow componentOxygen uptakeAdaptation Physiologicalpriming exerciseBicyclingbody regionso-2 uptake kineticsprior heavy exerciseMotor unit recruitmentTransitionPhysical therapyoxygen-uptake kineticsNeurology (clinical)Cycling
researchProduct

Human infant saliva peptidome is modified with age and diet transition.

2012

Abstract In order to describe developmental changes in human salivary peptidome, whole saliva was obtained from 98 infants followed longitudinally at 3 and 6 months of age. Data on teeth eruption and diet at the age of 6 months were also recorded. Salivary peptide extracts were characterised by label-free MALDI-MS. Peptides differentially expressed between the two ages, and those significantly affected by teeth eruption or introduction of solid foods were identified by MALDI TOF–TOF and LC ESI MS–MS. Out of 81 peaks retained for statistical analysis, 26 were overexpressed at the age of 6 months. Exposure to solid foods had a more pronounced effect on profiles (overexpression of nine peaks) …

AdultMalemedicine.medical_specialtySalivaAgingProteomeBiophysicsBiology01 natural sciencesBiochemistryTooth Eruption03 medical and health sciencesstomatognathic systemInternal medicinemedicineHumansStatistical analysisWhole salivaSalivary Proteins and PeptidesSalivaComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesChromatographyTransition (genetics)010401 analytical chemistryInfantFeeding Behavior0104 chemical sciencesEndocrinologySolid foodHistatinSalivary ProteinsFemalePeptides[SDV.AEN]Life Sciences [q-bio]/Food and NutritionJournal of proteomics
researchProduct

The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and…

1998

Purpose: We assess the results of bladder preservation for infiltrating bladder cancer. The potential for neoadjuvant chemotherapy followed by extensive transurethral resection and radiotherapy was evaluated in 40 patients with T2-T4a G2-G3 bladder carcinoma. Materials and Methods: From 1983 to 1995, 40 patients with bladder cancer underwent bladder sparing treatment, consisting of neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy. Most patients had T3G3 cancer. A deep transurethral resection biopsy was performed before and after chemotherapy, and an extensive transurethral resection was repeated at the end of radiotherapy. Of the patients 30 received cisplatin an…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentBladderUrologyTransitional cellSettore MED/24 - UrologiaCystectomyCarcinomaMedicineHumansAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellUrinary bladderBladder cancerRadiotherapybusiness.industryRemission InductionCarcinomaCancerMiddle Agedmedicine.diseaseVinblastineSurgeryRadiation therapyTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantFemaleDrug therapybusinessmedicine.drugFollow-Up Studies
researchProduct

The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome.

2015

<b><i>Objectives:</i></b> To identify the predictive variables affecting the outcome after radical surgery for bladder cancer by a newer statistical methodology, i.e. nonparametric combination (NPC). <b><i>Methods:</i></b> A multicenter study enrolled 1,312 patients who had undergone radical cystectomy for bladder cancer in 11 Italian oncological centers from January 1982 to December 2002. A statistical analysis<b> </b>of their medical history and diagnostic, pathological and postoperative variables was performed using a NPC test. The<b> </b>patients were included in a comprehensive database with medical history and cli…

AdultMalemedicine.medical_specialtyUrologyStatistics as TopicHydronephrosisnonparametric combinationCystectomyOutcome (game theory)Statistics NonparametricBladder cancer; Permutation test; PrognosisSettore MED/24 - UrologiaBladder cancer Prognosis Permutation testPredictive Value of TestsResamplingMedicineHumansPermutation testRadical surgeryIntensive care medicineAgedNeoplasm StagingRetrospective StudiesAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryBladder cancerProstatePermutation testsMiddle Agedmedicine.diseasePrognosisradical surgery for bladder; nonparametric combinationradical surgery for bladderSurgeryPatient Outcome Assessmentbladder cancer; Prognosis; Permutation testsItalyUrinary Bladder NeoplasmsBladdder Cancer Cystectomy outcome statistical methodologyData Interpretation StatisticalLymphatic MetastasisMultivariate AnalysisFemalePredictive variablesradical surgery for bladder nonparametric combinationbusiness
researchProduct

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

2006

PURPOSE: We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort. MATERIALS AND METHODS: NMP22 voided urine levels were measured in 2,871 patients who underwent office cystoscopy for monitoring previous stage Ta, T1 and/or CIS transitional cell carcinoma at 12 participating institutions. RESULTS: Patient characteristics varied considerably among institutions. Overall 1,045 patients (36.4%) had recurrent transitional cell carcinoma (range across institutions 13.6% to 54.3%). Median NMP22 was 5.5 U/ml (range across institutions 2.5 to 1…

AdultMalemedicine.medical_specialtyUrologyUrinary systemnuclear matrix protein 22Urologytumor markers biologicalBladder NeoplasmBiomarkers TumorMedicineHumansStage (cooking)bladderAgedGynecologyAged 80 and overCarcinoma Transitional CellUrinary bladderBladder cancermedicine.diagnostic_testbusiness.industryCarcinoma in situNuclear ProteinsReproducibility of ResultsCystoscopyMiddle Agedmedicine.diseasemedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsDisease Progressionbladder neoplasmFemaleNeoplasm Recurrence LocalbusinessThe Journal of urology
researchProduct

Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph nod…

2009

OBJECTIVE To investigate the associations between different overall or topographically restricted lymph node (LN) variables and cancer-specific survival (CSS) after radical cystectomy (RC) and extended LN dissection (LND) with curative intent in patients with LN-positive bladder cancer. PATIENTS AND METHODS Between 2001 and 2006, 152 patients had RC with standardized extended LND for bladder cancer with curative intent. Patients with positive LNs were stratified according to the median of the LN variables (LNs removed, number of positive LNs, LN density). CSS was related to overall and topographically restricted LN variables, e.g. different levels of LND, and relationships were tested by un…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyCystectomymedicineCarcinomaHumansLymph nodeAgedAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryHazard ratioCancerMiddle AgedPrognosismedicine.diseaseConfidence intervalSurgeryTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic MetastasisLymph Node ExcisionFemaleLymphadenectomyEpidemiologic MethodsbusinessBJU International
researchProduct

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic im…

1996

To analyze the effectiveness of adjuvant polychemotherapy after radical cystectomy for non-organ-confined transitional cell bladder cancer (Stages pT3b, pT4a, and/or pN1 or pN2).Of 166 consecutive patients undergoing cystectomy at two institutions from 1987 to 1993, 80 received adjuvant polychemotherapy with methotrexate, vinblastine, and cisplatin plus doxorubicin (MVAC) or epirubicin (MVEC), whereas 86 had cystectomy only. The patients were evaluated for relapse-free survival and length of progression-free interval on the basis of follow-up data obtained in 1995 and 1996.Kaplan-Meier analysis revealed a significantly higher progression-free rate for patients after adjuvant chemotherapy (P…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansProspective StudiesProspective cohort studyLymph nodeAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantLymphatic MetastasisDisease ProgressionFemalebusinessAdjuvantFollow-Up StudiesUrology
researchProduct

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study…

1995

A total of 83 patients with nonorgan-confined bladder cancer with or without lymph node metastases (tumor stages pT3b, pT4a and/or pN1, pN2) was evaluated in November 1993 for relapse-free and overall survival. All patients underwent radical cystectomy between 1987 and 1991, 38 underwent adjuvant polychemotherapy with methotrexate, vinblastine and cisplatin plus doxorubicin (M-VAC) or epirubicin (M-VEC). Of the 83 patients 49 had entered a prospective randomized trial comparing adjuvant to no adjuvant treatment. The protocol was activated in May 1987. Patient recruitment was concluded in December 1990 because an interim analysis of the 49 randomized patients revealed a significant prognosti…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastinelaw.inventionCystectomyRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesSurvival rateAgedEpirubicinCarcinoma Transitional CellUrinary bladderBladder cancerbusiness.industryMiddle AgedInterim analysismedicine.diseaseCombined Modality TherapyVinblastineSurgerySurvival Ratemedicine.anatomical_structureMethotrexateUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinbusinessmedicine.drugEpirubicinThe Journal of urology
researchProduct